XML 24 R27.htm IDEA: XBRL DOCUMENT v2.4.0.8
DESCRIPTION OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details) (USD $)
In Thousands, unless otherwise specified
Jun. 30, 2013
Apr. 30, 2013
Item
Dec. 31, 2012
Business Separation      
Number of independent publicly traded companies created as a result of the separation of businesses as approved by the Board of Directors   2  
Number of companies, which will continue to manage all development and commercial responsibilities under the LABA collaboration with GSK and associated potential royalty revenue   1  
Raw materials $ 3,531   $ 5,668
Work-in-process 4,709   1,846
Total inventory $ 8,240   $ 7,514